ATACANA GROUP Inc.

🔥 𝐊𝐞𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒 🔥 Promising new treatments were unveiled across various cancer types at this year's ASCO meeting: 𝐌𝐞𝐥𝐚𝐧𝐨𝐦𝐚 👉 Moderna/ Merck's personalized mRNA cancer vaccine mRNA-4157 showed durable 3-year efficacy in resected melanoma when combined with Keytruda (pembrolizumab). 👉 Philogen S.p.A.'s novel cytokine Nidlegy significantly improved relapse-free survival vs control in resectable melanoma with skin/nodal metastases. 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 👉 AstraZeneca's Imfinzi (durvalumab) may become a new consolidation option for limited-stage small cell lung cancer based on the ADRIATIC trial. 👉 Tagrisso (osimertinib) demonstrated potential to reshape treatment for unresectable Stage III EGFR-mutated non-small cell lung cancer in the LAURA study. 👉 Johnson & Johnson's subcutaneous Rybrevant (amivantamab) combo improved progression-free survival over IV administration in refractory EGFR+ NSCLC. 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 👉 Daiichi Sankyo US and AstraZeneca's Enhertu (trastuzumab deruxtecan) could become a new standard of care for patients with HER2 low and HER2 ultralow metastatic breast cancer following one or more lines of endocrine therapy patients with metastatic hormone receptor (HR)-positive HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. 𝐁𝐥𝐨𝐨𝐝 𝐂𝐚𝐧𝐜𝐞𝐫𝐬 👉 GSK's Blenrep (belantamab mafodotin) combo demonstrated efficacy in relapsed/refractory multiple myeloma, setting up a potential re-entry into the US market. 👉 Novartis' Scemblix (asciminib) achieved superior molecular response rates vs standard TKIs in newly diagnosed chronic myeloid leukemia. 𝐑𝐚𝐫𝐞 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 👉 An experimental immunotherapy lete-cel showed promising responses in rare sarcomas like myxoid/round cell liposarcoma and synovial sarcoma. 👉 Giving chemo-immunotherapy before surgery was found to be safe and well-tolerated for mesothelioma, potentially improving outcomes. 👉 Vimseltinib significantly reduced tumor volume and improved symptoms in tenosynovial giant cell tumor, an ultra-rare joint disease. With numerous practice-changing studies across cancer types, ASCO 2024 unveiled exciting advances that could reshape treatment paradigms in the coming years. We excel in post-congress intelligence follow-up research and analysis. Do you have intelligence gaps, and want to hear from key sources what they think and how the new data impacts your strategy? Email us at 📥 [email protected] #ASCO2024 #oncology #cancer #breastcancer #lungcancer #raresoldtumors #bloodcancers #mRNA #pharma #pharmaceutical #biotech #competitiveitelligence #insights #strategy

🚀 Recent trends indicate an increase in neuropsychiatry drug development! 👉 Over $40Bn in investments in the neuropsychiatric space over the last five years reflect a broader industry shift toward this relatively underserved area. Notably, these investments focused on schizophrenia therapies, marked by recent high-profile acquisitions. 👉 Prime examples include Bristol Myers Squibb’s $14Bn acquisition of Karuna Therapeutics and AbbVie’s $8.7Bn deal for Cerevel, highlighting big pharmaceutical companies’ interest in new schizophrenia treatments. 👉 Karuna’s KarXT, with a PDUFA action date of 26 September 2024, was the primary driver for its acquisition by Bristol Myers Squibb. Similarly, Cerevel’s emraclidine, currently in Ph2 trials with data expected in H2’24, was the catalyst for its acquisition by AbbVie. If approved, KarXT could become the first-to-market therapy with a new MoA for schizophrenia in over 50 years. Established players such as #JohnsonandJohnson, #Otsuka, and #Abbvie will need to consider how to stay competitive. Who do you think will lead in the schizophrenia space? Contact Atacana if you need to sharpen your competitive readiness initiatives for your upcoming launches! Email us at 📥 [email protected] #Schizophrenia #BMS #Biogen #BoehringerIngelheim #Nxera #Neurocrine #Amgen #Neumora #Sunovion #Supernus #Navitor #pharma #pharmaceuticals #biotech #competitiveintelligence

✨ Unveiling the Next Era in MASH Treatment at the Upcoming European Association for the Study of the Liver (EASL) Congress 2024! We’ll be on the lookout for exciting updates from: 👉 Madrigal Pharmaceuticals' Resmetirom (Rezdiffra): how is the first and only approved MASH therapy setting new standards in liver health? What are the latest news on real-world evidence, non-invasive diagnostics, and patient quality of life improvements? 🔬 New Data and Discussion around other Promising MoAs: 🔴 GLP-1 Analogs: Semaglutide (Novo Nordisk) and Tirzepatide’s (Eli Lily) 🔴 Glucagon/GLP-1 receptor dual agonists: Survodutide (BI) and Pemvidutide (Altimmune) 🔴 FGF-21 Analogs: Efruxifermin (Akero) and Pegozafermin (89bio) 🔴 Other MoAs: Sagimet’s Denifanstat (FASN inhibitor) and Ionis’s ION224 (DGAT2 inhibitor) 💡 What breakthrough in MASH treatment are you most excited to see at EASL 2024? Share your thoughts in the comments section below 👇 For more insights on the MASH space, email us at [email protected] #EASL2024 #LiverHealth #MASH #NASH #PharmaInnovation #MedicalResearch #competitiveintelligence

🩺 Is GPT already surpassing physicians? A head-to-head trial. A study recently published in NEMJ AI explores the capabilities of the latest GPT-4 model in the context of medical exams. This study assesses GPT-4's performance on the 2022 Israeli board residency exams across various medical specialties, comparing it to the results of 849 practicing physicians and earlier iterations like GPT-3.5. The findings indicate that GPT-4 not only surpassed GPT-3.5 but also outperformed a significant number of practicing doctors, demonstrating its potential as a valuable tool in medical education and decision-making. The study highlights GPT-4’s advanced problem-solving skills, particularly in higher-order management and imaging-related questions, suggesting promising applications in enhancing healthcare practices. AI tools will also be critical for pharma leaders, decision-makers, and almost everyone working with data, and they will transform the way we work.  At Atacana we are developing innovative AI tools to support winning strategies. If you would like to hear more, email us at 📥  [email protected]

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 31, 2024: Winners & Losers) 👇 👍 Bristol Myers Squibb Myers: secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma 🏥 AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis 🇪🇺 Sanofi Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD 🏅 Candel Therapeutics: Received FDA Orphan Drug Designation for CAN-3110 for recurrent high-grade glioma treatment. 🔬 @Soterios Pharma sees phase 2 win for alopecia cream as offering alternative to JAK domination 🌍 @SN Bioscience, following the FDA, EMA also Grants an Orphan Drug Designation to Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer. 🎉 Ori Biotech: Unveiled an automated cell therapy production platform, boosting manufacturing capabilities. 🔬 Cytiva: Launched a new CAR-T manufacturing platform, developed with @Kite for improved cell therapy production. 🔎 Cyclo Therapeutics, Inc.: Completed enrollment of the last patient in phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 treatment. 🧬 Syncromune®, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer 🧪 Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer 🧠 Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia 🌟 InxMed 应世生物 Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation 👐 Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria 📉 **Losers** 💔 Gilead Sciences’s Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths What are your thoughts on these developments? Share your insights below! Don't forget to follow for daily updates in the pharma and biotech industry. #pharmaceuticals #biotech #news #competitiveintelligence #atacanagroup

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 30, 2024: Winners & Losers) 👇 👁️ Merck buys EyeBio and its ophthalmology-focused trispecific antibody Restoret for $3 billion. 🎉 Ultragenyx secures a phase 3 victory for its gene therapy DTX401 for Glycogen Storage targeting glycogen storage diseases. 🔬 L'Oréal: Develops bioprinted skin that can feel, potentially revolutionizing the health and beauty industry. 🔍 Guardant Health's colorectal cancer blood test receives FDA approval.  🧠Eli Lilly and Company receives approval for Retevmo for Pediatric Indications, Non-Stimulant ADHD Drug. 💊 Johnson & Johnson reports positive phase 3 trial data for oral add-on therapy, seltorexant, treating MDD symptoms in insomnia patients. 🚀 Tris Pharma gets FDA approval for ONYDA XR, a once-daily oral suspension for treating ADHD. 💉 Bristol Myers Squibb: Receives FDA approval for Breyanzi, as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma 🏥 Baxter International Inc.'s study reveals expanded dialysis can significantly reduce death rates. 🔬 CSL Seqirus partners with BARDA for the production of 4.8 million bird flu vaccines. 💡 BioNTech SE: Expands mRNA vaccine activity in Africa with CEPI. 🎮 Akili Interactive: Is sold for $34 million, marking a notable transaction in the ADHD game development sector. 💉 Orna Therapeutics: Acquires ReNAgade Therapeutics, expanding throughRNA-based medicine delivery technology. Cytiva: Launches a new CAR-T manufacturing platform. 📈 **Losers** ⚖️ Pfizer averts some claims in ongoing Chantix legal battle related to its smoking cessation drug. 💬 What are your thoughts on these developments? Who will be the next winner or loser? Comment below and follow us for more updates! #pharmaceuticals #biotech #news #competitiveintelligence #atacanagroup

⚡Breaking the Silence: Timely Diagnosis for a Better Multiple Sclerosis Journey Over 2.8 million people worldwide live with MS, yet 83% of countries face challenges that hinder early diagnosis. MS diagnosis is complex, requiring multiple tests to rule out other conditions, which delays treatment and prolongs suffering. This World MS Day, we advocate for improved MS training for healthcare professionals, innovative research, and advanced diagnostic tools to ensure timely and accurate diagnosis for all. Together, we are building informed, caring communities and systems that support people diagnosed with MS #MyMSDiagnosis #WorldMSDay #atacanagroup Source: worldmsday.org

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 29, 2024: Winners & Losers) 👇 🎯 Orna Therapeutics: Acquires ReNAgade Therapeutics, enhancing RNA-based medicines delivery capabilities. 💵 Agios Pharmaceuticals: Sells cancer drug #vorasidenib for $905M, potential to generate over $1B in U.S. sales. ⭐ Asahi Kasei: Prepares to buy Calliditas Therapeutics for more than $1B, securing access to FDA-approved Tarpeyo. 🏁 Galvanize Therapeutics, Inc.: Receives FDA clearance for the INUMI Flex Endoscopic Needle, Expanding its #Aliya Pulsed Electric Field (PEF) Portfolio for Soft Tissue Ablation 👶 ILiAD Biotechnologies, LLC: Develops pertussis shot as part of childhood vaccines. 🥇 Vetter Pharma: Wins the Best Managed Companies Award for 2024. 🔍 Roche: FDA grants Priority Review #inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation 🔬 Amgen: The U.S. Food and Drug Administration approved Bkemv, the first biosimilar to AstraZeneca rare blood disorder treatment Soliris. 😞 **Losers** 👨💼 Takeda: amid restructuring campaign, plots 641 layoffs at 2 Massachusetts sites 🚫 NS Pharma, Inc.: Viltepso fails a confirmatory trial for Duchenne muscular dystrophy Viltepso, placing its 2020 accelerated FDA approval in jeopardy. 🔓 Cencora | Pharma solutions: Novartis, Bayer | Pharmaceuticals, GSK, and eight other major pharmaceutical firms disclosed the compromise of their patients' information following Cencora's cyberattack Any other exciting news in pharma that took place today? Don't forget to follow ATACANA GROUP Inc. for daily updates #pharmaceuticals #biotech #news #competitiveintelligence #atacanagroup

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 28, 2024) 👇 💊Novartis: Planning regulatory submissions for rare kidney diseases this year. 🧪Johnson & Johnson: Acquired Numab Therapeutics AG Therapeutics’ bispecific antibody NM26 for Phase II studies. 🧬Innovent Biologics: Achieved primary endpoints in Phase 3 trial for moderate to severe plaque psoriasis. 💡RevolKa Ltd.: Signed a master service agreement with Daiichi Sankyo US for protein engineering technology. 🦠Moderna: Reported smaller-than-expected loss for Q1 due to strong Covid vaccine sales. 🔬Merck Group: Acquired gene therapy tools maker for $600 million. 🧫Biogen: Acquired immune drugmaker HI-Bio for $1.15 billion. 🏭Eli Lilly and Company: Invested an additional $5.3 billion in its Indiana plant. 🎯AstraZeneca: Set a sales target of $80 billion by 2030. 🤝Novavax: Experienced a significant turnaround following its partnership with Sanofi. 📉 LOSERS: 🤷♀️AstraZeneca: Failed to show overall survival benefit in non-small cell lung cancer patients. 🚫 Novo Nordisk: FDA Ad-com voted against Icodec once-weekly insulin in Type1 diabetes, 7-4 💰Pfizer: Plans to save $1.5 billion by 2027 through cost-cutting measures. What are your thoughts on these developments? Share your insights below! Don't forget to follow ATACANA GROUP Inc. for daily updates on Pharma winners and losers! #pharmaceuticals #biotech #news #artificialintelligence #competitiveintelligence

🔥 ASCO Annual Meeting Begins This Week! 🔥 The ASCO (American Society of Clinical Oncology) Annual Meeting, the world's largest oncology congress, kicks off this week.   A total of 5,900 abstracts have been released, showcasing the latest research and advancements in cancer treatment and care.   This year, care delivery and quality care are at the forefront, with 891 abstracts dedicated to these crucial aspects.   In terms of tumor-specific research, breast, gastrointestinal, and lung cancers are the focus, accounting for the largest number of abstracts.   The oncology community is eagerly anticipating detailed presentations that have the potential to revolutionize treatment protocols and improve patient outcomes.   For congress coverage or post-ASCO intelligence question follow-ups, email us at 📥 [email protected] #ASCO2024 #ONCOLOGY #cancer #competitiveintelligence #insights #pharma #biotech